Senate Finance Committee: Gilead Sciences' HCV drugs are aimed at profit, not patient care

Gilead Sciences' Sovaldi and Harvoni have played a significant role in revolutionizing the hepatitis C field of care, but the pharmaceutical company has been criticized for the high price tag of its drugs.

A single course of Sovaldi costs $84,000, while the later released drug Harvoni has a $94,500 cost for a course of treatment. The Senate Finance Committee released a 144-page report on its findings from an 18-month, bipartisan investigation of the drugs' pricing and marketing. Senate Finance Committee Ranking Member Sen. Ron Wyden (D-Ore.) and senior committee member Sen. Chuck Grassley (R-Iowa) headed up the report.

The report concludes Gilead Sciences' primary concern was maximizing revenue, while affordability was not a focus. "Gilead pursued a calculated scheme for pricing and marketing its Hepatitis C drug based on one primary goal, maximizing revenue, regardless of the human consequences," said Sen. Wyden in the report. "If Gilead's approach to pricing is the future of how blockbuster drugs are launched, it will cost billions and billions of dollars to treat just a fraction of patients."

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast